|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
J04AK05
|
|
gptkbp:brand
|
gptkb:Sirturo
|
|
gptkbp:CASNumber
|
843663-66-1
|
|
gptkbp:category
|
antineoplastic agent
diarylquinoline
|
|
gptkbp:chemicalFormula
|
C32H31BrN2O2
|
|
gptkbp:contraindication
|
severe liver impairment
concomitant use with strong CYP3A4 inducers
|
|
gptkbp:cost
|
high (in some countries)
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminationHalfLife
|
5.5 months
|
|
gptkbp:essentialMedicine
|
yes
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(C=C1)C2=NC3=CC=CC=C3C(=N2)C4=CC(=C(C=C4)Br)OCC5=CC=CC=C5)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bedaquiline
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
inhibits mycobacterial ATP synthase
|
|
gptkbp:MedlinePlusID
|
a613018
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
555.5 g/mol
|
|
gptkbp:notRecommendedFor
|
gptkb:drug-sensitive_tuberculosis
gptkb:latent_tuberculosis
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:patentExpired
|
2023 (in some countries)
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:prescribedWith
|
other antituberculosis drugs
|
|
gptkbp:proteinBinding
|
>99.9%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
5388906
DB08903
|
|
gptkbp:riskFactor
|
increased risk of death compared to placebo
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
QT prolongation
arthralgia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
1S8T1W5V6F
|
|
gptkbp:usedFor
|
treatment of multidrug-resistant tuberculosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:WHOPrequalification
|
yes
|
|
gptkbp:bfsParent
|
gptkb:BDQ
|
|
gptkbp:bfsLayer
|
7
|